Prof. Kang's phase 3 study on Nexava attracting world interests.

Published: 2006-10-26 06:57:00

Updated: 2006-10-26 06:57:00

Prof. Kang Yun-kyu, the oncologist of Seoul Asan Hospital who was reputed with the anti-cancer drug therapy presented his paper titled "A new paradigm of anti-cancer therapy" covering his clinical studies on Nexava, an anti-cancer drug, on Oct. 13 during the conference of PSMO (The Philippine Soc...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK